Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11672800 Combination therapies with EHMT2 inhibitors

Patent 11672800 was granted and assigned to Epizyme on June, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Epizyme
Epizyme
0
Date Filed
April 20, 2018
0
Date of Patent
June 13, 2023
0
Patent Applicant
Epizyme
Epizyme
0
Patent Application Number
16606833
0
Patent Citations
‌
US Patent 8785444 Thiazoles and pyrazoles useful as kinase inhibitors
0
‌
US Patent 8986994 Substituted pyridines and pyrimidines
0
‌
US Patent 9018209 Compounds and methods for the treatment of viruses and cancer
0
‌
US Patent 9487504 Imidazolyl analogs as syk inhibitors
0
‌
US Patent 9284272 Inhibitors of histone methyltransferase G9a
0
‌
US Patent 7935710 Microbicidal pyrimidine or triazine for preventing sexual HIV transmission
0
‌
US Patent 8026248 HIV inhibiting pyrimidine derivatives
0
‌
US Patent 8575165 Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds
0
‌
US Patent 8604042 Bi-aryl meta-pyrimidine inhibitors of kinases
0
‌
US Patent 8680113 BMI-1 protein expression modulators
0
Patent Citations Received
‌
US Patent 11945785 Pyrazine compounds as inhibitors of FLT3
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11672800
0
Patent Primary Examiner
‌
Craig D Ricci
0
CPC Code
‌
A61K 31/505
0
‌
A61K 45/06
0
‌
A61K 31/404
0

Find more entities like US Patent 11672800 Combination therapies with EHMT2 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.